EUS-guided Transenteric Drainage With a Novel Lumen-apposing Metal Stent

Acute Cholecystitis Clinical Trial

Official title:

EUS-guided Transenteric Drainage With a Novel Lumen-apposing Metal Stent for the Management of Pancreato-biliary Diseases: a Multi-national, Multicenter Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03002051
• Other study ID #: SPAXUS version 3.0
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: May 2019

Study information

• Verified date: December 2019
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate clinical efficacy and safety of a novel lumen-apposing FCSEMS for EUS-guided transenteric drainage of PFC or of biliary tree including GB

Description:

Patients with the following conditions would be recruited for drainage under EUS guidance with the new lumen apposing FCSEMS

• Symptomatic or infected pancreatic pseudocyst or walled-off necrosis (WON) (SPAXUS 16 or 10 mm)

• Acute cholecystitis by inoperable malignant diseases (SPAXUS 10 mm)

• Acute cholecystitis by benign conditions with high-risk for operation (SPAXUS 10 mm)

• Long-term cholecystostomy at high-risk for operation (SPAXUS 10 mm)

• Symptomatic malignant obstruction of the distal CBD with unsuccessful transpapillary approach (the diameter of the CBD > 10 mm) (SPAXUS 8 or 10 mm)

Outcome paramaters include technical and clinical success, adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 114
• Est. completion date: May 2019
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

Patient must meet all of the following inclusion criteria to be eligible for enrollment into the study.

• Pancreatobiliary diseases that are eligible for EUS-guided transenteric drainage

• The patient who aged from 20 to 80 years. Legally acceptable representative must be capable of giving written informed consent prior to participation in this study

• Target lesion that is accessible through the transenteric approach

• The woman of child-bearing age must be negative from the pregnancy test in order to participate in this study

• The patient who is willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures

• The patients should not have any unacceptable conditions (e.g., physiological, familyism, social, geographical) for medical follow-up and adaptation of the study.

Exclusion Criteria:

Patient presenting with any of the following will not be included in the study.

• Inaccessible to EUS-guided approach

• Bleeding tendency: International normalized ratio (INR) of prothrombin time < 1.5 or platelet conunt < 60,000/mm3

• Patients with Disseminated Intravascular Coagulation syndrome(DIC)

• Patients who have been taking medicines that can cause hemorrhage (e.g., Aspirin, Wafarin etc.)

• Patients with other serious disease or medical condition

• Patients with past medical history of significant neurologic or Psychiatric disorders such as dementia or seizure

• Unstable heart disease despite of treatment, recent myocardial infarction within 6 month (Even though MI was diagnosed within 6 months, if it becomes stable presently, the patient can be possible to participate).

Related Conditions & MeSH terms

• Acute Cholecystitis
• Biliary Obstruction
• Cholecystitis
• Cholecystitis, Acute
• Necrosis
• Pancreatic Necrosis
• Pancreatic Pseudocyst

Intervention

Device:
• EUS-guided drainage
Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage. EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen. After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm). After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen. After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance.

Locations

Country	Name	City	State
China	Chinese University of Hong Kong	Hong Kong	Hong Kong

Sponsors (2)

Lead Sponsor	Collaborator
Chinese University of Hong Kong	SoonChunHyang University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical success for pancreatic fluid collections	? Clinical success of pancreatic fluid collections; Peudocyst: resolution more than 50% in the initial size of cyst.; Walled-off necrosis: resolution of PFC without the need for additional interventions after endoscopic interventions.	8 hrs
Primary	Clinical success for acute cholecystitis	- Afebrile for 8 hours, tolerating diet, absence of abdominal sign, or 20% decrease in white cell count.	8hrs
Primary	Clinical success for obstructive jaundice	- A decrease in total bilirubin to < 50 % of the pre-stenting value within 2 weeks.	2 weeks
Secondary	Techincal success	- Satisfactory access, placement of stent and drainage.	1 day
Secondary	Adverse events	Bleeding: any hemorrhagic event during or after the procedure that required endotherapy, radiological interventions, blood product transfusion, or inpatient observation.; Perforation: perforation of the GI tract or cystic wall on imaging studies with peritonitis signs.; Pneumoperitoneum or pneumoretroperitoneum: intraperitoneal or retroperitoneal air on imaging study.; Stent migration: dislocation of the stent into the lumen or the GI tract on imaging study	30 day